Distinguished in Atherosclerosis

Dr. Dominick J. Angiolillo

Interventional Cardiology | Cardiology
University Of Florida Jacksonville Physicians, Inc.
655 W 8th St, 
Jacksonville, FL 
Accepting New Patients
Distinguished in Atherosclerosis
University Of Florida Jacksonville Physicians, Inc.
655 W 8th St, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dominick Angiolillo is an Interventional Cardiologist and a Cardiologist in Jacksonville, Florida. Dr. Angiolillo is rated as a Distinguished provider by MediFind in the treatment of Atherosclerosis. His top areas of expertise are Coronary Heart Disease, Acute Coronary Syndrome, Heart Attack, Percutaneous Coronary Intervention (PCI), and Stent Placement. Dr. Angiolillo is currently accepting new patients.

His clinical research consists of co-authoring 643 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 29 articles and participated in 3 clinical trials in the study of Atherosclerosis.

Specialties
Interventional Cardiology
Cardiology
Licenses
Internal Medicine in FL
Hospital Affiliations
Southeast Georgia Health System -- Camden Campus
Baptist Health Medical Center - Jacksonville
Shands Jacksonville
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

UNIVERSITY OF FLORIDA JACKSONVILLE PHYSICIANS, INC.
655 W 8th St, Jacksonville, FL 32209

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After Undergoing Percutaneous Coronary Intervention:The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) - 2 Study
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After Undergoing Percutaneous Coronary Intervention:The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) - 2 Study
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Drug
Study Drugs: Ticagrelor, Clopidogrel
Study Phase: Phase 4
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Pharmacodynamic Effects of Different Ticagrelor Maintenance Dosing Regimens With and Without Aspirin in Patients With Diabetes Mellitus: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-7 Study
Pharmacodynamic Effects of Different Ticagrelor Maintenance Dosing Regimens With and Without Aspirin in Patients With Diabetes Mellitus: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-7 Study
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Ticagrelor, Aspirin, Clopidogrel
Study Phase: Phase 4
Switching From Standard of Care Dual Antiplatelet Treatment (DAPT) Regimens With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition (DPI) With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study
Switching From Standard of Care Dual Antiplatelet Treatment (DAPT) Regimens With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition (DPI) With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study
Enrollment Status: Completed
Publish Date: April 26, 2023
Intervention Type: Drug
Study Drugs: Clopidogrel, Prasugrel, Ticagrelor, Aspirin, Rivaroxaban
Study Phase: Phase 4
A Study to Evaluate RenalGuard® System Safety & Efficacy When Compared With Standard Care in the Prevention of Contrast Induced NephRopathy in the SettinG of a Catheterization Laboratory
A Study to Evaluate RenalGuard® System Safety & Efficacy When Compared With Standard Care in the Prevention of Contrast Induced NephRopathy in the SettinG of a Catheterization Laboratory
Enrollment Status: Unknown
Publish Date: February 16, 2023
Intervention Type: Drug, Device
Study Phase: Phase 3
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Drugs: Ticagrelor, Prasugrel
Study Phase: Phase 4
Pharmacodynamic Effects of Low-dose Rivaroxaban in Combination With Antiplatelet Therapies in Patients With Coronary and Peripheral Artery Disease Manifestations
Pharmacodynamic Effects of Low-dose Rivaroxaban in Combination With Antiplatelet Therapies in Patients With Coronary and Peripheral Artery Disease Manifestations
Enrollment Status: Completed
Publish Date: June 27, 2022
Intervention Type: Drug
Study Phase: Phase 4
Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy for Patients Undergoing Cardiac Catheterization at UF Health Jacksonville
Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy for Patients Undergoing Cardiac Catheterization at UF Health Jacksonville
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Device
Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity
Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Other, Drug
Study Phase: Phase 4
A Randomized Comparison of Platelet Inhibition Using a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Prior Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-6 Study
A Randomized Comparison of Platelet Inhibition Using a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Prior Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-6 Study
Enrollment Status: Completed
Publish Date: November 30, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility Study With Point-of-care Pharmacodynamic and Genetic Testing
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility Study With Point-of-care Pharmacodynamic and Genetic Testing
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 4
Adjunctive Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With New Generation P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor (VORA-PRATIC): A Prospective, Randomized, Pharmacodynamic Study
Adjunctive Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With New Generation P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor (VORA-PRATIC): A Prospective, Randomized, Pharmacodynamic Study
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 4
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 4
Platelet Inhibition With CANgrelor and Crushed TICagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: The CANTIC Study
Platelet Inhibition With CANgrelor and Crushed TICagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: The CANTIC Study
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug, Other
Study Phase: Phase 4
Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study
Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study
Enrollment Status: Completed
Publish Date: February 12, 2020
Intervention Type: Drug
Study Phase: Phase 4
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT): A Prospective Randomized Study
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT): A Prospective Randomized Study
Enrollment Status: Completed
Publish Date: April 06, 2018
Intervention Type: Drug
Study Phase: Phase 4
Effect of D-allulose Ingestion on the Glucose and Insulin Response to a Standardized Oral Sucrose Load
Effect of D-allulose Ingestion on the Glucose and Insulin Response to a Standardized Oral Sucrose Load
Enrollment Status: Completed
Publish Date: July 11, 2017
Intervention Type: Dietary supplement, Other
Study Phase: Phase 2
Utilization of Lexiscan (Regadenoson)in the Cardiac Catheterization Lab to Achieve Maximal Hyperemia for Coronary Physiologic Assessment With Fractional Flow Reserve
Utilization of Lexiscan (Regadenoson)in the Cardiac Catheterization Lab to Achieve Maximal Hyperemia for Coronary Physiologic Assessment With Fractional Flow Reserve
Enrollment Status: Completed
Publish Date: June 23, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 17 Less Clinical Trials

643 Total Publications

Impact of PCSK9 inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled analysis of two Randomized Trials.
Impact of PCSK9 inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled analysis of two Randomized Trials.
Journal: Thrombosis and haemostasis
Published: October 10, 2025
Similar Doctors
Distinguished in Atherosclerosis
Dr. Youssef M. Al-Saghir
Interventional Cardiology | Cardiology
Distinguished in Atherosclerosis
Dr. Youssef M. Al-Saghir
Interventional Cardiology | Cardiology

First Coast Cardiovascular Institute, LLC

1681 Eagle Harbor Pkwy, Suite B, 
Orange Park, FL 
 (17.0 miles away)
904-644-0092
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Youssef Al-Saghir is an Interventional Cardiologist and a Cardiologist in Orange Park, Florida. Dr. Al-Saghir is rated as a Distinguished provider by MediFind in the treatment of Atherosclerosis. His top areas of expertise are Arterial Embolism, Angina, Carotid Artery Disease, Transmyocardial Revascularization, and Stent Placement. Dr. Al-Saghir is currently accepting new patients.

Distinguished in Atherosclerosis
Dr. Sumant Lamba
Interventional Cardiology | Cardiology
Distinguished in Atherosclerosis
Dr. Sumant Lamba
Interventional Cardiology | Cardiology

First Coast Cardiovascular Institute, LLC

7011 A C Skinner Pkwy, Suite 160, 
Jacksonville, FL 
 (8.5 miles away)
904-493-3333
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sumant Lamba is an Interventional Cardiologist and a Cardiologist in Jacksonville, Florida. Dr. Lamba is rated as a Distinguished provider by MediFind in the treatment of Atherosclerosis. His top areas of expertise are Heart Failure, Heart Failure with Preserved Ejection Fraction (HFpEF), Pediatric Myocarditis, Necrosis, and Atherectomy. Dr. Lamba is currently accepting new patients in some locations.

Distinguished in Atherosclerosis
Dr. Bashar S. Saikaly
Cardiology
Distinguished in Atherosclerosis
Dr. Bashar S. Saikaly
Cardiology

Drs Baker And Gilmour MD PA

12276 San Jose Blvd, Suite 617, 
Jacksonville, FL 
 (14.0 miles away)
904-733-4444
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bashar Saikaly is a Cardiologist in Jacksonville, Florida. Dr. Saikaly is rated as a Distinguished provider by MediFind in the treatment of Atherosclerosis. His top areas of expertise are Angina, Coronary Heart Disease, Atherosclerosis, and Glucocorticoid-Remediable Aldosteronism. Dr. Saikaly is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Angiolillo's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile